Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study

The RTOG 85-31 study has indicated that adjuvant hormonotherapy is particularly effective in prostate cancer (PC) patients with a high Glisson score. Long-term adjuvant hormonotherapy is not warranted in patients with a total Glisson score of 2-6. Exception is patients with disseminated locally adva...

Full description

Bibliographic Details
Main Authors:	Miljenko V. Pilepich, Kathryn Winter, Colleen A. Lawton, Robert E. Krisch, Harvey B. Wolkov, Benjamin Movsas, Eugen B. Hug, Sucha O. Asbell, David Grignon
Format:	Article
Language:	Russian
Published:	ABV-press 2020-02-01
Series:	Onkourologiâ
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/1089

id	doaj-f21745a18eb54a0fb152401ac4429012
record_format	Article
spelling	doaj-f21745a18eb54a0fb152401ac44290122021-07-29T08:41:45ZrusABV-pressOnkourologiâ 1726-97761996-18122020-02-0131596510.17650/1726-9776-2007-3-1-59-65972Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 studyMiljenko V. Pilepich0Kathryn Winter1Colleen A. Lawton2Robert E. Krisch3Harvey B. Wolkov4Benjamin Movsas5Eugen B. Hug6Sucha O. Asbell7David Grignon8California University, Los Angeles, School of Medicine, Los Angeles, CAGroup of Radiation Therapy in Oncology, Philadelphia, PAWisconsin Medical College, Milluoki, WIUniversity of Pennsylvania State, Philadelphia, PAAssociation of Radiology of Sacramento, Sacramento, CAFox Chase Cancer Center, Philadelphia, PAHitchcock Dartmouth Medical Center, Lebanon, NHAlbert Einstein Medical Center, Philadelphia, PAWhane State University, Detroit, MIThe RTOG 85-31 study has indicated that adjuvant hormonotherapy is particularly effective in prostate cancer (PC) patients with a high Glisson score. Long-term adjuvant hormonotherapy is not warranted in patients with a total Glisson score of 2-6. Exception is patients with disseminated locally advanced tumors, in whom neoadjuvant androgenic suppression (RTOG 86-10 protocol) considerably improves the results of treatment. Long-term adjuvant hormonotherapy may be the method of choice in treating PC patients with a poor prognosis.https://oncourology.abvpress.ru/oncur/article/view/1089
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	Miljenko V. Pilepich Kathryn Winter Colleen A. Lawton Robert E. Krisch Harvey B. Wolkov Benjamin Movsas Eugen B. Hug Sucha O. Asbell David Grignon
spellingShingle	Miljenko V. Pilepich Kathryn Winter Colleen A. Lawton Robert E. Krisch Harvey B. Wolkov Benjamin Movsas Eugen B. Hug Sucha O. Asbell David Grignon Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study Onkourologiâ
author_facet	Miljenko V. Pilepich Kathryn Winter Colleen A. Lawton Robert E. Krisch Harvey B. Wolkov Benjamin Movsas Eugen B. Hug Sucha O. Asbell David Grignon
author_sort	Miljenko V. Pilepich
title	Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
title_short	Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
title_full	Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
title_fullStr	Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
title_full_unstemmed	Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
title_sort	adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase iii rtog 85-31 study
publisher	ABV-press
series	Onkourologiâ
issn	1726-9776 1996-1812
publishDate	2020-02-01
description	The RTOG 85-31 study has indicated that adjuvant hormonotherapy is particularly effective in prostate cancer (PC) patients with a high Glisson score. Long-term adjuvant hormonotherapy is not warranted in patients with a total Glisson score of 2-6. Exception is patients with disseminated locally advanced tumors, in whom neoadjuvant androgenic suppression (RTOG 86-10 protocol) considerably improves the results of treatment. Long-term adjuvant hormonotherapy may be the method of choice in treating PC patients with a poor prognosis.
url	https://oncourology.abvpress.ru/oncur/article/view/1089
work_keys_str_mv	AT miljenkovpilepich adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT kathrynwinter adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT colleenalawton adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT robertekrisch adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT harveybwolkov adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT benjaminmovsas adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT eugenbhug adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT suchaoasbell adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study AT davidgrignon adjuvantandrogenicblockadeafterteleradiotherapyforprostatecancerlongtermresultsofphaseiiirtog8531study
_version_	1721252417312391168

Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study

Similar Items